SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

細胞治療と遺伝子治療製造サービス市場

出版：MarketsandMarkets

Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Cancer, Orthopedic), Application (Clinical, Commercial), End User (Pharma & Biotech, Academia) – Global Forecast to 2026
種別英文調査報告書
出版MarketsandMarkets
出版年月2021年7 月
ページ数285
図表数392
–
レポート目次 お問合せ
–細胞治療と遺伝子治療製造サービス市場のタイプ（同種異系、自家、ウイルスベクター、非ウイルスベクター）、適応症（癌、整形外科）、用途（臨床、商業）、エンドユーザー（製薬およびバイオテクノロジー、アカデミア）The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.“The clinical manufacturing segment accounted for the highest growth rate in thecell & gene therapy manufacturing servicesmarket, byapplication, during the forecast period”The cell & gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing on the basis of application. The clinical manufacturing segment accounted for the highest growth rate in the cell & gene therapy manufacturing servicesmarket during the forecast period. This segment’s high growth rate can be attributed to increasing government funding for cancer research and the increasing number of cell & gene therapy clinical trials.“Pharmaceutical & biotechnology companies segment accounted for the highest CAGR”Based on end users, the cell & gene therapy manufacturing servicesmarket is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. During the forecast periodpharmaceutical & biotechnology companies accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.“Cell Therapy segment accounted for the highest CAGR”Based on type, the cell & gene therapy manufacturing servicesmarket is segmented intocell therapy and gene therapy. The cell therapy segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the increasing awareness about cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis.“Infectious diseases segment accounted for the highest CAGR”Based on indication, the cell & gene therapy manufacturing servicesmarket is segmented into oncology diseases, cardiovascular diseases, orthopedic diseases, ophthalmology diseases, infectious diseases, central nervous system disorders, and other indications. Theinfectious diseases segment accounted for the highest growth rate during the forecast period. The growth of this segment is attributed to the rising clinical trials for the development of cell therapies owing to the increasing prevalence of infectious diseases.“Asia Pacific: The fastest-growing countryin thecell & gene therapy manufacturing servicesmarket”TheCell & gene therapy manufacturing servicesmarket is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Increasing pharmaceutical R&D spending, the growing trend of outsourcing drug discovery services, growing life sciences research, and increasing government initiatives for healthcare research are the factors driving the growth of the cell & gene therapy manufacturing servicesmarket in this region. The primary interviews conducted for this report can be categorized as follows:•By Respondent: Supply Side- 70%, and Demand Side -30%•By Designation (Supply Side): Managers – 45%, CXOs and Directors – 30%, and Executives- 25%•By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%Lists of Companies Profiled in the Report:•Thermo Fisher Scientific, Inc. (US)• Merck KGaA (Germany)•Charles River Laboratories (US)• Lonza (Switzerland)•Catalent, Inc. (US)•WuXiAppTec (China)•Takara Bio Inc. (Japan)•NIKON CORPORATION (Japan)•FUJIFILM Holdings Corporation (Japan)•F. Hoffmann-La Roche Ltd. (Switzerland)•Oxford Biomedica plc (UK)•Cell and Gene Therapy Catapult (UK)•The Discovery Labs LLC (US)•RoslinCT (Scotland)•JRS PHARMA (Germany)•FinVector (Finland)•ABL, Inc. (US)•Resilience (US)•BioCentriq (US)•Porton Biopharma Limited (England)•Andelyn Biosciences (US)•Commercializing Living Therapies (Canada)•Vibalogics (US)•AnemocyteSrl (Italy)•ElevateBio (US)Research Coverage:This report provides a detailed picture of the cell & gene therapy manufacturing servicesmarket. It aims at estimating the size and future growth potential of the market across different segments, such as type, indication, application, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell & gene therapy manufacturing servicesmarket and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

目次

1INTRODUCTION451.1OBJECTIVES OF THE STUDY451.2MARKET DEFINITION451.2.1INCLUSIONS & EXCLUSIONS451.3MARKET SCOPE461.3.1MARKETS COVERED461.3.2YEARS CONSIDERED IN THE REPORT471.4CURRENCY471.5LIMITATIONS471.6STAKEHOLDERS482RESEARCH METHODOLOGY492.1RESEARCH DATA49FIGURE 1RESEARCH DESIGN492.1.1SECONDARY DATA502.1.2PRIMARY DATA50FIGURE 2PRIMARY SOURCES51FIGURE 3CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BREAKDOWN OF PRIMARIES512.1.2.1Key industry insights522.2MARKET SIZE ESTIMATION53FIGURE 4MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 202053FIGURE 5AVERAGE MARKET SIZE ESTIMATION, 202054FIGURE 6CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: CAGR PROJECTIONS, 2021–202655FIGURE 7CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES562.3MARKET BREAKDOWN AND DATA TRIANGULATION57FIGURE 8DATA TRIANGULATION METHODOLOGY572.4RESEARCH ASSUMPTIONS582.5RISK ANALYSIS583EXECUTIVE SUMMARY59FIGURE 9CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)59FIGURE 10CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)60FIGURE 11CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)60FIGURE 12CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)61FIGURE 13GEOGRAPHICAL SNAPSHOT OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET624PREMIUM INSIGHTS634.1CELL & GENE THERAPY MANUFACTURING SERVICES MARKET OVERVIEW63FIGURE 14HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES TO DRIVE MARKET GROWTH634.2NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE & COUNTRY (2020)64FIGURE 15THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020644.3CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY APPLICATION, 202064FIGURE 16THE CLINICAL MANUFACTURING SEGMENT DOMINATED THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET IN 2020644.4CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2021–202665FIGURE 17ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD655MARKET OVERVIEW665.1INTRODUCTION665.2MARKET DYNAMICS66FIGURE 18CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES66TABLE 1CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: IMPACT ANALYSIS675.2.1DRIVERS675.2.1.1High incidence of cancer and other target diseases675.2.1.2Increasing investments in pharmaceutical R&D68FIGURE 19INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2016685.2.1.3Investments in advanced technologies by CDMOs695.2.1.4Increasing partnerships and agreements between pharmaceutical companies and CDMOs695.2.2RESTRAINTS705.2.2.1High operational costs associated with cell & gene therapy manufacturing705.2.3OPPORTUNITIES705.2.3.1Rising demand for cell & gene therapies705.2.3.2Increasing number of cell & gene therapy clinical trials715.2.4CHALLENGES715.2.4.1Risk of mutagenesis and other unwanted outcomes715.2.5TRENDS715.2.5.1Expansion in emerging countries715.3IMPACT OF THE COVID-19 OUTBREAK ON THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET72FIGURE 20CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SCENARIO, PRE-COVID-19 VS. POST-COVID-19 IMPACT, 2019–2021735.4TECHNOLOGICAL ANALYSIS735.5CASE STUDIES745.5.1CGT CATAPULT PROVIDED ITS EXPERTISE IN THERAPIES DEVELOPMENT AND MANUFACTURING TO CREATE A NEW PRECLINICAL DEVELOPMENT PLAN FOR PURESPRING THERAPEUTICS’ GENE THERAPY TECHNOLOGY FOR KIDNEY DISEASES745.6RANGES/SCENARIO74FIGURE 21SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET745.7TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES75FIGURE 22REVENUE SHIFT & NEW POCKETS FOR CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS755.8PRICING ANALYSIS755.9VALUE CHAIN ANALYSIS75FIGURE 23VALUE CHAIN ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: HARVESTING AND CRYOPRESERVATION PHASES ADD MAXIMUM VALUE765.10ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET76FIGURE 24ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET76TABLE 2SUPPLY CHAIN ECOSYSTEM775.11PORTER’S FIVE FORCES ANALYSIS78TABLE 3CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS785.11.1THREAT FROM NEW ENTRANTS785.11.2THREAT FROM SUBSTITUTES785.11.3BARGAINING POWER OF BUYERS785.11.4BARGAINING POWER OF SUPPLIERS785.11.5INTENSITY OF COMPETITIVE RIVALRY795.12REGULATORY ANALYSIS795.12.1NORTH AMERICA795.12.1.1US795.12.1.2Canada795.12.2EUROPE795.12.2.1Germany795.12.2.2France795.12.2.3UK805.12.2.4Rest of Europe805.12.3ASIA PACIFIC805.12.3.1China805.12.3.2Japan805.12.3.3Rest of Asia Pacific815.12.3.3.1India815.12.3.3.2Australia and New Zealand815.12.4LATIN AMERICA815.12.5MIDDLE EAST & AFRICA825.13PATENT ANALYSIS82FIGURE 25NUMBER OF PATENT APPLICATIONS FILED FOR CELL & GENE THERAPY MANUFACTURING SERVICES, JANUARY 2010–DECEMBER 2020826CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE836.1INTRODUCTION84TABLE 4CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)846.2CELL THERAPY84TABLE 5CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)84TABLE 6CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)85TABLE 7NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)85TABLE 8EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)85TABLE 9ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)866.2.1ALLOGENEIC86TABLE 10ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)86TABLE 11ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)87TABLE 12NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)87TABLE 13EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)87TABLE 14ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)886.2.1.1Mesenchymal stem cells886.2.1.1.1MSCs are ideal for cell therapy because of their immunosuppressive and tissue repair properties88TABLE 15ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)88TABLE 16NORTH AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)89TABLE 17EUROPE: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)89TABLE 18ASIA PACIFIC: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)896.2.1.2T-cells906.2.1.2.1Allogeneic T-Cells are immediately available because of cryopreserved batches90TABLE 19ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)90TABLE 20NORTH AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)90TABLE 21EUROPE: ALLOGENEIC T-CELLS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)91TABLE 22ASIA PACIFIC: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)916.2.1.3Induced pluripotent stem cells916.2.1.3.1Growing adoption Of IPSCs in research to drive market growth91TABLE 23ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)92TABLE 24NORTH AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)92TABLE 25EUROPE: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)92TABLE 26ASIA PACIFIC: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)936.2.1.4Natural killer cells936.2.1.4.1Allogeneic natural killer cell therapies are used for advanced hepatocellular carcinoma patients93TABLE 27ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)93TABLE 28NORTH AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)94TABLE 29EUROPE: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)94TABLE 30ASIA PACIFIC: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)946.2.1.5Hematopoietic stem cells956.2.1.5.1Stem cells from a donor are used for allogeneic transplantation95TABLE 31ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)95TABLE 32NORTH AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)95TABLE 33EUROPE: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)96TABLE 34ASIA PACIFIC: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)96 6.2.1.6Other allogeneic cells96TABLE 35OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)97TABLE 36NORTH AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)97TABLE 37EUROPE: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)97TABLE 38ASIA PACIFIC: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)986.2.2AUTOLOGOUS98TABLE 39AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)98TABLE 40AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)99TABLE 41NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)99TABLE 42EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)99TABLE 43ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1006.2.2.1T-cells1006.2.2.1.1T-cells are major components of the adaptive immune system100TABLE 44AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)101TABLE 45NORTH AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)101TABLE 46EUROPE: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)101TABLE 47ASIA PACIFIC: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1026.2.2.2Hematopoietic stem cells1026.2.2.2.1Hematopoietic stem cells are used to establish marrow and bone function102TABLE 48AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)102TABLE 49NORTH AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)103TABLE 50EUROPE: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)103TABLE 51ASIA PACIFIC: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1036.2.2.3Mesenchymal stem cells1046.2.2.3.1Mesenchymal stem cells are present in the umbilical cord, bone marrow, & fat tissue104TABLE 52AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)104TABLE 53NORTH AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)104TABLE 54EUROPE: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)105TABLE 55ASIA PACIFIC: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1056.2.2.4Natural killer cells1056.2.2.4.1NK Cells are used in the treatment of tumors and infectious diseases105TABLE 56AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)106TABLE 57NORTH AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)106TABLE 58EUROPE: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)106TABLE 59ASIA PACIFIC: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1076.2.2.5Other autologous cells107TABLE 60OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)107TABLE 61NORTH AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)108TABLE 62EUROPE: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)108TABLE 63ASIA PACIFIC: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1086.2.3VIRAL VECTOR109TABLE 64VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)109TABLE 65VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)109TABLE 66NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)110TABLE 67EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)110TABLE 68ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1106.2.3.1Retroviral vectors1116.2.3.1.1Retroviral vectors are the most used viral vectors for cell therapy manufacturing111TABLE 69RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)111TABLE 70NORTH AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)111TABLE 71EUROPE: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)112TABLE 72ASIA PACIFIC: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1126.2.3.2Adeno-associated virus vectors1126.2.3.2.1AAV vector-based techniques are used for car-t cell therapy development112TABLE 73ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)113TABLE 74NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)113TABLE 75EUROPE: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)113TABLE 76ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1146.2.3.3Other viral vectors114TABLE 77OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)114TABLE 78NORTH AMERICA: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)115TABLE 79EUROPE: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)115TABLE 80ASIA PACIFIC: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1156.3GENE THERAPY116TABLE 81GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)116TABLE 82GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)116TABLE 83NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)117TABLE 84EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)117TABLE 85ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1176.3.1NON-VIRAL VECTORS118TABLE 86NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)118TABLE 87NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)118TABLE 88NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)119TABLE 89EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)119TABLE 90ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1196.3.1.1Oligonucleotides1206.3.1.1.1North America accounted for the largest share of the oligonucleotides market120TABLE 91OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)120TABLE 92NORTH AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)120TABLE 93EUROPE: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)121TABLE 94ASIA PACIFIC: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1216.3.1.2Other non-viral vectors121TABLE 95OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)122TABLE 96NORTH AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)122TABLE 97EUROPE: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)122TABLE 98ASIA PACIFIC: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1236.3.2VIRAL VECTORS123TABLE 99VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)123TABLE 100VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)124TABLE 101NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)124TABLE 102EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)124TABLE 103ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1256.3.2.1Retroviral vectors1256.3.2.1.1Retroviral vectors possess the ability to replicate within a cell125TABLE 104RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)126TABLE 105NORTH AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)126TABLE 106EUROPE: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)126TABLE 107ASIA PACIFIC: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1276.3.2.2Adeno-associated virus vectors1276.3.2.2.1Adeno-associated virus vectors have low toxicity127TABLE 108ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)128TABLE 109NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)128TABLE 110EUROPE: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)128TABLE 111ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1296.3.2.3Other viral vectors129TABLE 112OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)129TABLE 113NORTH AMERICA: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)130TABLE 114EUROPE: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)130TABLE 115ASIA PACIFIC: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)1307CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION1317.1INTRODUCTION132TABLE 116CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)1327.2ONCOLOGY DISEASES1327.2.1THE DEMAND FOR CELL & GENE THERAPIES IS INCREASING WITH THE RISING NUMBER OF CANCER CASES WORLDWIDE132TABLE 117CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)133TABLE 118NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)133TABLE 119EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)134TABLE 120ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)1347.3CARDIOVASCULAR DISEASES1347.3.1GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES DRIVES THE MARKET GROWTH134TABLE 121CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)135TABLE 122NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)135TABLE 123EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)135TABLE 124ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)1367.4ORTHOPEDIC DISEASES1367.4.1CELL THERAPY FOR ORTHOPEDIC DISEASES ELIMINATES POST-TREATMENT COMPLICATIONS136TABLE 125CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY REGION, 2019–2026 (USD MILLION)136TABLE 126NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)137TABLE 127EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)137TABLE 128ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)1377.5OPTHALMOLOGY DISEASES1387.5.1STEM CELL THERAPIES CAN BE USED FOR THE RESTORATION & PRESERVATION OF VISION; KEY FACTOR DRIVING MARKET GROWTH138TABLE 129CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)138TABLE 130NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)138TABLE 131EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)139TABLE 132ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)1397.6CENTRAL NERVOUS SYSTEM DISORDERS1397.6.1INCREASING INCIDENCE OF SPINAL MUSCULAR ATROPHY SUPPORTS THE MARKET GROWTH139TABLE 133CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2019–2026 (USD MILLION)140TABLE 134NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)140TABLE 135EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)140TABLE 136ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)1417.7INFECTIOUS DISEASES1417.7.1THE INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE THE MARKET GROWTH OF THIS SEGMENT141TABLE 137CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)142TABLE 138NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)142TABLE 139EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)142TABLE 140ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)1437.8OTHER INDICATIONS143TABLE 141CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)143TABLE 142NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)144TABLE 143EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)144TABLE 144ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)1448CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION1458.1INTRODUCTION146TABLE 145CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)1468.2CLINICAL MANUFACTURING1468.2.1THE RISING NUMBER OF CLINICAL TRIALS FOR CELL & GENE THERAPIES IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT146TABLE 146CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)147TABLE 147NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)147TABLE 148EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)147TABLE 149ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)1488.3COMMERCIAL MANUFACTURING1488.3.1MARKET GROWTH CAN BE ATTRIBUTED TO THE INCREASING APPROVALS OF CELL & GENE THERAPY PRODUCTS FOR COMMERCIAL MANUFACTURING148TABLE 150CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)148TABLE 151NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)149TABLE 152EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)149TABLE 153ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)1499CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER1509.1INTRODUCTION151TABLE 154CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)1519.2PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES1519.2.1GROWING NUMBER OF CELL & GENE THERAPIES IN THE R&D PIPELINE TO DRIVE THE MARKET GROWTH151TABLE 155CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)152TABLE 156NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)152TABLE 157EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)153TABLE 158ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)1539.3ACADEMIC & RESEARCH INSTITUTES1539.3.1INCREASE IN LIFE SCIENCES R&D EXPENDITURE TO CONTRIBUTE TO THE GROWTH OF THIS SEGMENT153TABLE 159CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)154TABLE 160NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)154TABLE 161EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)155TABLE 162ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)1559.4OTHER END USERS155TABLE 163CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)156TABLE 164NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)156TABLE 165EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)156TABLE 166ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)15710CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION15810.1INTRODUCTION159TABLE 167CELL & GENE THERAPY MANUFACTURING THERAPY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)15910.2NORTH AMERICA159FIGURE 26NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT160TABLE 168NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)160TABLE 169NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)161TABLE 170NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)161TABLE 171NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)161TABLE 172NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)162TABLE 173NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)162TABLE 174NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)162TABLE 175NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)163TABLE 176NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)163TABLE 177NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)163TABLE 178NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)164TABLE 179NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)16410.2.1US16410.2.1.1Growing focus on cancer research in the US will drive market growth164TABLE 180US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)165TABLE 181US: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)165TABLE 182US: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)165TABLE 183US: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)166TABLE 184US: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)166TABLE 185US: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)166TABLE 186US: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)167TABLE 187US: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)167TABLE 188US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)167TABLE 189US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)168TABLE 190US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)16810.2.2CANADA16810.2.2.1Growth in Canada can be attributed to the rising funding for stem cell research in the country168TABLE 191CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)169TABLE 192CANADA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)169TABLE 193CANADA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)170TABLE 194CANADA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)170TABLE 195CANADA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)170TABLE 196CANADA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)171TABLE 197CANADA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)171TABLE 198CANADA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)171TABLE 199CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)172TABLE 200CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)172TABLE 201CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)17210.3EUROPE173TABLE 202EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)173TABLE 203EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)173TABLE 204EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)173TABLE 205EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)174TABLE 206EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)174TABLE 207EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)174TABLE 208EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)175TABLE 209EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)175TABLE 210EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)175TABLE 211EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)176TABLE 212EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)176TABLE 213EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)17610.3.1GERMANY17710.3.1.1Government funding for life science R&D and basic cancer research will drive market growth177TABLE 214GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)177TABLE 215GERMANY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)177TABLE 216GERMANY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)178TABLE 217GERMANY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)178TABLE 218GERMANY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)178TABLE 219GERMANY: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)179TABLE 220GERMANY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)179TABLE 221GERMANY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)179TABLE 222GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)180TABLE 223GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)180TABLE 224GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)18010.3.2UK18110.3.2.1The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth181TABLE 225UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)181TABLE 226UK: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)181TABLE 227UK: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)182TABLE 228UK: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)182TABLE 229UK: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)182TABLE 230UK: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)183TABLE 231UK: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)183TABLE 232UK: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)183TABLE 233UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)184TABLE 234UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)184TABLE 235UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)18410.3.3FRANCE18510.3.3.1Growth can be attributed to rising government funding for cancer research185TABLE 236FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)185TABLE 237FRANCE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)185TABLE 238FRANCE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)186TABLE 239FRANCE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)186TABLE 240FRANCE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)186TABLE 241FRANCE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)187TABLE 242FRANCE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)187TABLE 243FRANCE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)187TABLE 244FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)188TABLE 245FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)188TABLE 246FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)18810.3.4REST OF EUROPE189TABLE 247ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)189TABLE 248ROE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)189TABLE 249ROE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)190TABLE 250ROE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)190TABLE 251ROE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)190TABLE 252ROE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)191TABLE 253ROE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)191TABLE 254ROE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)191TABLE 255ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)192TABLE 256ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)192TABLE 257ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)19210.4ASIA PACIFIC193FIGURE 27ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT193TABLE 258ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)194TABLE 259ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)194TABLE 260ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)194TABLE 261ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)195TABLE 262ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)195TABLE 263ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)195TABLE 264ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)196TABLE 265ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)196TABLE 266ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)196TABLE 267ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)197TABLE 268ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)197TABLE 269ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)19710.4.1CHINA19810.4.1.1The growing pharmaceutical industry and rising number of CDMOs in the country will drive market growth198TABLE 270CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)198TABLE 271CHINA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)199TABLE 272CHINA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)199TABLE 273CHINA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)199TABLE 274CHINA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)200TABLE 275CHINA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)200TABLE 276CHINA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)200TABLE 277CHINA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)201TABLE 278CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)201TABLE 279CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)201TABLE 280CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)20210.4.2JAPAN20210.4.2.1Research collaborations and growing geriatric population—key growth drivers in Japan202TABLE 281JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)203TABLE 282JAPAN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)203TABLE 283JAPAN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)203TABLE 284JAPAN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)204TABLE 285JAPAN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)204TABLE 286JAPAN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)204TABLE 287JAPAN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)205TABLE 288JAPAN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)205TABLE 289JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)205TABLE 290JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)206TABLE 291JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)20610.4.3REST OF ASIA PACIFIC206TABLE 292ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)207TABLE 293ROAPAC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)207TABLE 294ROAPAC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)208TABLE 295ROAPAC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)208TABLE 296ROAPAC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)208TABLE 297ROAPAC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)209TABLE 298ROAPAC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)209TABLE 299ROAPAC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)209TABLE 300ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)210TABLE 301ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)210TABLE 302ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)21010.5LATIN AMERICA21110.5.1RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET211TABLE 303LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)211TABLE 304LATAM: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)211TABLE 305LATAM: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)212TABLE 306LATAM: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)212TABLE 307LATAM: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)212TABLE 308LATAM: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)213TABLE 309LATAM: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)213TABLE 310LATAM: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)213TABLE 311LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)214TABLE 312LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)214TABLE 313LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)21410.6MIDDLE EAST & AFRICA21510.6.1MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D215TABLE 314MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)215TABLE 315MEA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)216TABLE 316MEA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)216TABLE 317MEA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)216TABLE 318MEA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)217TABLE 319MEA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)217TABLE 320MEA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)217TABLE 321MEA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)218TABLE 322MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)218TABLE 323MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)218TABLE 324MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)219 11COMPETITIVE LANDSCAPE22011.1OVERVIEW22011.2KEY PLAYER STRATEGIES/RIGHT TO WIN221FIGURE 28KEY PLAYER STRATEGIES IN THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, 2018–202122111.3MARKET SHARE ANALYSIS222FIGURE 29CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE ANALYSIS, BY KEY PLAYER, 202022211.4REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS223FIGURE 30REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS22311.5COMPANY EVALUATION QUADRANT22411.5.1STARS22411.5.2EMERGING LEADERS22411.5.3PERVASIVE PLAYERS22411.5.4EMERGING COMPANIES224FIGURE 31CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT, 202022511.6COMPANY EVALUATION QUADRANT: START-UPS/SMES22611.6.1PROGRESSIVE COMPANIES22611.6.2STARTING BLOCKS22611.6.3RESPONSIVE COMPANIES22611.6.4DYNAMIC COMPANIES226FIGURE 32CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 202022711.7SERVICE FOOTPRINT OF COMPANIES228TABLE 325SERVICE PORTFOLIO ANALYSIS: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)22811.8REGIONAL FOOTPRINT OF COMPANIES229TABLE 326REGIONAL FOOTPRINT OF COMPANIES: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)22911.9COMPETITIVE SCENARIO230TABLE 327CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DEALS, JANUARY 2018–JUNE 2021230TABLE 328CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2018 –JUNE 202123112COMPANY PROFILES23212.1KEY MARKET PLAYERS232(Business Overview, Services Offered, Recent Developments, and MnM View)*12.1.1THERMO FISHER SCIENTIFIC, INC.232TABLE 329THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW232FIGURE 33THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)23312.1.2MERCK KGAA237TABLE 330MERCK KGAA: BUSINESS OVERVIEW237FIGURE 34MERCK KGAA: COMPANY SNAPSHOT (2020)23812.1.3CHARLES RIVER LABORATORIES241TABLE 331CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW241FIGURE 35CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)24212.1.4LONZA245TABLE 332LONZA: BUSINESS OVERVIEW245FIGURE 36LONZA: COMPANY SNAPSHOT (2020)24612.1.5CATALENT, INC.251TABLE 333CATALENT, INC.: BUSINESS OVERVIEW251FIGURE 37CATALENT, INC.: COMPANY SNAPSHOT (2020)25212.1.6TAKARA BIO INC.257TABLE 334TAKARA BIO INC.: BUSINESS OVERVIEW257FIGURE 38TAKARA BIO INC.: COMPANY SNAPSHOT (2020)25812.1.7OXFORD BIOMEDICA PLC260TABLE 335OXFORD BIOMEDICA PLC: BUSINESS OVERVIEW260FIGURE 39OXFORD BIOMEDICA PLC: COMPANY SNAPSHOT (2020)26012.1.8CELL AND GENE THERAPY CATAPULT263TABLE 336CELL AND GENE THERAPY CATAPULT: BUSINESS OVERVIEW263FIGURE 40CELL AND GENE THERAPY CATAPULT: COMPANY SNAPSHOT (2020)26412.1.9F. HOFFMANN-LA ROCHE LTD.267TABLE 337F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW267FIGURE 41F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)26712.1.10FUJIFILM HOLDINGS CORPORATION269TABLE 338FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW269FIGURE 42FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)27012.1.11WUXI APPTEC272TABLE 339WUXI APPTEC: BUSINESS OVERVIEW272FIGURE 43WUXI APPTEC: COMPANY SNAPSHOT (2020)27312.1.12NIKON CORPORATION275TABLE 340NIKON CORPORATION: BUSINESS OVERVIEW275FIGURE 44NIKON CORPORATION: COMPANY SNAPSHOT (2020)27612.2OTHER PLAYERS27712.2.1THE DISCOVERY LABS LLC277TABLE 341THE DISCOVERY LABS LLC: BUSINESS OVERVIEW27712.2.2ROSLINCT278TABLE 342ROSLINCT: BUSINESS OVERVIEW27812.2.3JRS PHARMA279TABLE 343JRS PHARMA: BUSINESS OVERVIEW27912.2.4FINVECTOR280TABLE 344FINVECTOR: BUSINESS OVERVIEW28012.2.5ABL, INC.281TABLE 345ABL, INC.: BUSINESS OVERVIEW28112.2.6RESILIENCE, INC.283TABLE 346RESILIENCE, INC.: BUSINESS OVERVIEW28312.2.7BIOCENTRIQ284TABLE 347BIOCENTRIQ: BUSINESS OVERVIEW28412.2.8PORTON BIOPHARMA LIMITED285TABLE 348PORTON BIOPHARMA LIMITED: BUSINESS OVERVIEW28512.2.9ANDELYN BIOSCIENCES28612.2.10COMMERCIALIZING LIVING THERAPIES28612.2.11VIBALOGICS28712.2.12ANEMOCYTE SRL28712.2.13ELEVATE BIO288* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.13APPENDIX28913.1DISCUSSION GUIDE28913.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL29613.3AVAILABLE CUSTOMIZATIONS29813.4RELATED REPORTS29813.5AUTHOR DETAILS299

お問合せフォーム

    お問合せフォーム

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com

    航空宇宙＆防衛の最新記事8件